{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:02:47Z","timestamp":1792274567453,"version":"4.4.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00428-022-03417-1","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:07:04Z","timestamp":1666760824000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The International Consensus Classification of myelodysplastic syndromes and related entities"],"prefix":"10.1007","volume":"482","author":[{"given":"Robert P.","family":"Hasserjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rozman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"26","key":"3417_CR1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371(26):2477\u20132487","journal-title":"N Engl J Med"},{"issue":"12","key":"3417_CR2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472\u20131478","journal-title":"Nat Med"},{"issue":"43","key":"3417_CR3","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","volume":"8","author":"P Valent","year":"2017","unstructured":"Valent P, Orazi A, Steensma DP et al (2017) Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget 8(43):73483\u201373500","journal-title":"Oncotarget"},{"issue":"25","key":"3417_CR4","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati L, Galli A, Travaglino E et al (2017) Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 129(25):3371\u20133378","journal-title":"Blood"},{"issue":"11","key":"3417_CR5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"21","key":"3417_CR6","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","volume":"126","author":"CA Cargo","year":"2015","unstructured":"Cargo CA, Rowbotham N, Evans PA et al (2015) Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 126(21):2362\u20132365","journal-title":"Blood"},{"issue":"16","key":"3417_CR7","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","volume":"128","author":"PL Greenberg","year":"2016","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2016) Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood 128(16):2096\u20132097","journal-title":"Blood"},{"issue":"1","key":"3417_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126(1):9\u201316","journal-title":"Blood"},{"issue":"26","key":"3417_CR9","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488\u20132498","journal-title":"N Engl J Med"},{"issue":"1","key":"3417_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/j.seminhematol.2016.10.002","volume":"54","author":"M Jan","year":"2017","unstructured":"Jan M, Ebert BL, Jaiswal S (2017) Clonal hematopoiesis. Semin Hematol 54(1):43\u201350","journal-title":"Semin Hematol"},{"issue":"11","key":"3417_CR11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","volume":"138","author":"A Galli","year":"2021","unstructured":"Galli A, Todisco G, Catamo E et al (2021) Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood 138(11):965\u2013976","journal-title":"Blood"},{"issue":"4","key":"3417_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.18273","volume":"198","author":"EJ Choi","year":"2022","unstructured":"Choi EJ, Cho YU, Hur EH et al (2022) Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome. Br J Haematol 198(4):703\u2013712","journal-title":"Br J Haematol"},{"issue":"14","key":"3417_CR13","first-page":"1161","volume":"135","author":"IA van Zeventer","year":"2020","unstructured":"van Zeventer IA, de Graaf AO, Wouters H et al (2020) Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood 135(14):1161\u20131170","journal-title":"Blood"},{"issue":"1","key":"3417_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato T, Dumitriu B, Hosokawa K et al (2015) Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 373(1):35\u201347","journal-title":"N Engl J Med"},{"key":"3417_CR15","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA (2017) Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 3:17028","journal-title":"Nat Rev Dis Primers"},{"issue":"27","key":"3417_CR16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628\u20132638","journal-title":"N Engl J Med"},{"issue":"16","key":"3417_CR17","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5(16):3203\u20133215","journal-title":"Blood Adv"},{"issue":"1","key":"3417_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.2019000940","volume":"136","author":"L Sun","year":"2020","unstructured":"Sun L, Babushok DV (2020) Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood 136(1):36\u201349","journal-title":"Blood"},{"issue":"20","key":"3417_CR19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","volume":"135","author":"RP Hasserjian","year":"2020","unstructured":"Hasserjian RP, Steensma DP, Graubert TA, Ebert BL (2020) Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood 135(20):1729\u20131738","journal-title":"Blood"},{"issue":"11","key":"3417_CR20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T et al (2020) Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52(11):1219\u20131226","journal-title":"Nat Genet"},{"issue":"1","key":"3417_CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","volume":"18","author":"NK Gillis","year":"2017","unstructured":"Gillis NK, Ball M, Zhang Q et al (2017) Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol 18(1):112\u2013121","journal-title":"Lancet Oncol"},{"issue":"13","key":"3417_CR22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D et al (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"24","key":"3417_CR23","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood.2019001610","volume":"134","author":"V Shanmugam","year":"2019","unstructured":"Shanmugam V, Parnes A, Kalyanaraman R, Morgan EA, Kim AS (2019) Clinical utility of targeted next-generation sequencing-based screening of peripheral blood in the evaluation of cytopenias. Blood 134(24):2222\u20132225","journal-title":"Blood"},{"issue":"4","key":"3417_CR24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.leu.2404571","volume":"21","author":"A Matsuda","year":"2007","unstructured":"Matsuda A, Germing U, Jinnai I et al (2007) Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 21(4):678\u2013686","journal-title":"Leukemia"},{"issue":"1","key":"3417_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","volume":"20","author":"M Della Porta","year":"2015","unstructured":"Della Porta M, Travaglino E, Boveri E et al (2015) Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 20(1):66\u201375","journal-title":"Leukemia"},{"issue":"1","key":"3417_CR26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","volume":"29","author":"MG Della Porta","year":"2014","unstructured":"Della Porta MG, Travaglino E, Boveri E et al (2014) Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 29(1):66\u201375","journal-title":"Leukemia"},{"issue":"11","key":"3417_CR27","first-page":"E420","volume":"96","author":"SA Wang","year":"2021","unstructured":"Wang SA, Ok CY, Kim AS et al (2021) Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol 96(11):E420\u2013E423","journal-title":"Am J Hematol"},{"issue":"1","key":"3417_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajcp\/aqaa046","volume":"154","author":"AJ Siddon","year":"2020","unstructured":"Siddon AJ, Hasserjian RP (2020) How I diagnose low-grade myelodysplastic syndromes. Am J Clin Pathol 154(1):5\u201314","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"3417_CR29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","volume":"7","author":"DP Steensma","year":"2012","unstructured":"Steensma DP (2012) Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep 7(4):310\u2013320","journal-title":"Curr Hematol Malig Rep"},{"key":"3417_CR30","unstructured":"Swerdlow SH CE, Harris NL, Jaffe ES, Pileria SA, Stein H, Thiele J, Arber D, Hasserjian RP, LeBeau MM, Orazi A, Siebert R eds (2017) WHO classification of tumours of haematopoietic and lymphoid tissues (ed revised 4th edition). Lyon: International Agency for Research on Cancer"},{"issue":"4","key":"3417_CR31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ijlh.12826","volume":"40","author":"G Tang","year":"2018","unstructured":"Tang G, Medeiros LJ, Wang SA (2018) How I investigate clonal cytogenetic abnormalities of undetermined significance. Int J Lab Hematol 40(4):385\u2013391","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"3417_CR32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17921","volume":"196","author":"A Hama","year":"2022","unstructured":"Hama A, Hasegawa D, Manabe A et al (2022) Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization. Br J Haematol 196(4):1031\u20131039","journal-title":"Br J Haematol"},{"issue":"13","key":"3417_CR33","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood-2017-09-765214","volume":"131","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Strahm B (2018) How I treat myelodysplastic syndromes of childhood. Blood 131(13):1406\u20131414","journal-title":"Blood"},{"issue":"13","key":"3417_CR34","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/bloodadvances.2022007359","volume":"6","author":"X Calvo","year":"2022","unstructured":"Calvo X, Roman-Bravo D, Garcia-Gisbert N et al (2022) Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Adv 6(13):3921\u20133931","journal-title":"Blood Adv"},{"issue":"20","key":"3417_CR35","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2020002206","volume":"4","author":"X Calvo","year":"2020","unstructured":"Calvo X, Garcia-Gisbert N, Parraga I et al (2020) Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Adv 4(20):5285\u20135296","journal-title":"Blood Adv"},{"issue":"10","key":"3417_CR36","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","volume":"104","author":"P Valent","year":"2019","unstructured":"Valent P, Orazi A, Savona MR et al (2019) Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML) CMML variants and pre-CMML conditions. Haematologica 104(10):1935\u20131949","journal-title":"Haematologica"},{"issue":"6","key":"3417_CR37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2017-04-779579","volume":"130","author":"D Selimoglu-Buet","year":"2017","unstructured":"Selimoglu-Buet D, Badaoui B, Benayoun E et al (2017) Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood 130(6):832\u2013835","journal-title":"Blood"},{"issue":"5","key":"3417_CR38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1309\/FU04P779U310R3EE","volume":"126","author":"SA Wang","year":"2006","unstructured":"Wang SA, Galili N, Cerny J et al (2006) Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 126(5):789\u2013797","journal-title":"Am J Clin Pathol"},{"key":"3417_CR39","unstructured":"Hakim NM, Tam W, A. P, Tonk V, Orazi A (2021) Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations. Leukemia Research Reports"},{"issue":"8","key":"3417_CR40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.34119","volume":"128","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD, Garcia-Manero G, Kantarjian HM (2022) Time to blur the blast boundaries. Cancer 128(8):1568\u20131570","journal-title":"Cancer"},{"issue":"3","key":"3417_CR41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","volume":"139","author":"E Estey","year":"2022","unstructured":"Estey E, Hasserjian RP, Dohner H (2022) Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood 139(3):323\u2013332","journal-title":"Blood"},{"issue":"1","key":"3417_CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1309\/AJCPI9C8UILYQTNS","volume":"144","author":"K Foucar","year":"2015","unstructured":"Foucar K, Anastasi J (2015) Acute myeloid leukemia with recurrent cytogenetic abnormalities. Am J Clin Pathol 144(1):6\u201318","journal-title":"Am J Clin Pathol"},{"key":"3417_CR43","doi-asserted-by":"crossref","unstructured":"Konoplev S, Tang G, Wang X et al (2021) Oligoblastic (<20%) myeloid neoplasms with KMT2A (MLL) rearrangement show significant overlap with acute myeloid leukemia (AML) and should be regarded as AML. Blood 138(Suppl 1):793","DOI":"10.1182\/blood-2021-153749"},{"issue":"6","key":"3417_CR44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"3","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K et al (2019) NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922\u2013933","journal-title":"Blood Adv"},{"issue":"9","key":"3417_CR45","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","volume":"3","author":"SS Patel","year":"2019","unstructured":"Patel SS, Ho C, Ptashkin RN et al (2019) Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv 3(9):1540\u20131545","journal-title":"Blood Adv"},{"issue":"23","key":"3417_CR46","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/ijms21238975","volume":"21","author":"F Forghieri","year":"2020","unstructured":"Forghieri F, Nasillo V, Paolini A et al (2020) NPM1-mutated myeloid neoplasms with <20% blasts: a really distinct clinico-pathologic entity? Int J Mol Sci 21(23):8975","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3417_CR47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2013.096420","volume":"99","author":"HJ Rogers","year":"2014","unstructured":"Rogers HJ, Vardiman JW, Anastasi J et al (2014) Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica 99(5):821\u2013829","journal-title":"Haematologica"},{"issue":"6","key":"3417_CR48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41379-021-00741-w","volume":"34","author":"H Fang","year":"2021","unstructured":"Fang H, Yabe M, Zhang X et al (2021) Myelodysplastic syndrome with t(6;9)(p22;q34.1)\/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol. 34(6):1143\u20131152","journal-title":"Mod Pathol."},{"issue":"12","key":"3417_CR49","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"1","key":"3417_CR50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","volume":"96","author":"J Peng","year":"2016","unstructured":"Peng J, Zuo Z, Fu B et al (2016) Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol 96(1):65\u201371","journal-title":"Eur J Haematol"},{"issue":"5","key":"3417_CR51","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bjh.16628","volume":"189","author":"L Wu","year":"2020","unstructured":"Wu L, Li X, Xu F et al (2020) NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy. Br J Haematol 189(5):982\u2013984","journal-title":"Br J Haematol"},{"issue":"3","key":"3417_CR52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0609.2002.02770.x","volume":"69","author":"K Kaneda","year":"2002","unstructured":"Kaneda K, Kojima K, Takeuchi M et al (2002) Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome? Eur J Haematol 69(3):165\u2013170","journal-title":"Eur J Haematol"},{"key":"3417_CR53","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango JE, et al. (2022) Molecular international prognostic scoring system for myelodysplastic syndromes. N Engl J Med Evid 1(7)"},{"issue":"5","key":"3417_CR54","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","volume":"62","author":"X Chen","year":"2021","unstructured":"Chen X, Othus M, Wood BL et al (2021) Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leuk Lymphoma 62(5):1226\u20131233","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3417_CR55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41375-021-01498-6","volume":"36","author":"X Chen","year":"2022","unstructured":"Chen X, Fromm JR, Naresh KN (2022) \u201cBlasts\u201d in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward? Leukemia 36(2):327\u2013332","journal-title":"Leukemia"},{"issue":"1","key":"3417_CR56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-012-1565-4","volume":"92","author":"P Font","year":"2013","unstructured":"Font P, Loscertales J, Benavente C et al (2013) Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 92(1):19\u201324","journal-title":"Ann Hematol"},{"issue":"2","key":"3417_CR57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PAI.0b013e318030dec7","volume":"15","author":"CH Dunphy","year":"2007","unstructured":"Dunphy CH, O\u2019Malley DP, Perkins SL, Chang CC (2007) Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias. Appl Immunohistochem Mol Morphol 15(2):154\u2013159","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"3417_CR58","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","volume":"90","author":"E Estey","year":"1997","unstructured":"Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90(8):2969\u20132977","journal-title":"Blood"},{"key":"3417_CR59","doi-asserted-by":"crossref","unstructured":"Grob T, Al Hinai AS, Sanders MA, et al. (2022) Molecular characterization of mutant Tp53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood","DOI":"10.1182\/blood.2021014472"},{"issue":"2","key":"3417_CR60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima H, Yoshizato T, Yoshida K et al (2017) Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 49(2):204\u2013212","journal-title":"Nat Genet"},{"issue":"4","key":"3417_CR61","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2643-3230.BCD-21-0155","volume":"3","author":"AJ Menssen","year":"2022","unstructured":"Menssen AJ, Khanna A, Miller CA et al (2022) Convergent clonal evolution of signaling gene mutations is a hallmark of myelodysplastic syndrome progression. Blood Cancer Discov 3(4):330\u2013345","journal-title":"Blood Cancer Discov"},{"key":"3417_CR62","unstructured":"Greenberg PL, Stone RM, Al-Kali A et al (2022) NCCN Guidelines Myelodysplastic Syndromes (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf).\u00a0Accessed 1 Sep 2022"},{"issue":"15","key":"3417_CR63","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","volume":"29","author":"M Jadersten","year":"2011","unstructured":"Jadersten M, Saft L, Smith A et al (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 29(15):1971\u20131979","journal-title":"J Clin Oncol"},{"issue":"10","key":"3417_CR64","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP et al (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 26(10):1549\u20131556","journal-title":"Nat Med"},{"issue":"2","key":"3417_CR65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E et al (2015) SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 126(2):233\u2013241","journal-title":"Blood"},{"issue":"20","key":"3417_CR66","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2020005488","volume":"136","author":"Y Nagata","year":"2020","unstructured":"Nagata Y, Zhao R, Awada H et al (2020) Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood 136(20):2249\u20132262","journal-title":"Blood"},{"issue":"11","key":"3417_CR67","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M et al (2021) Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol 39(11):1223\u20131233","journal-title":"J Clin Oncol"},{"key":"3417_CR68","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","volume":"6","author":"M Gerstung","year":"2015","unstructured":"Gerstung M, Pellagatti A, Malcovati L et al (2015) Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 6:5901","journal-title":"Nat Commun"},{"issue":"12","key":"3417_CR69","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti A, Armstrong RN, Steeples V et al (2018) Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood 132(12):1225\u20131240","journal-title":"Blood"},{"issue":"6","key":"3417_CR70","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","volume":"25","author":"PS Woll","year":"2014","unstructured":"Woll PS, Kjallquist U, Chowdhury O et al (2014) Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25(6):794\u2013808","journal-title":"Cancer Cell"},{"issue":"2","key":"3417_CR71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E et al (2020) SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 136(2):157\u2013170","journal-title":"Blood"},{"issue":"5","key":"3417_CR72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clml.2020.01.005","volume":"20","author":"B Xiong","year":"2020","unstructured":"Xiong B, Xue M, Yu Y, Wu S, Zuo X (2020) SF3B1 mutation but not ring sideroblasts identifies a specific group of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia. Clin Lymphoma Myeloma Leuk. 20(5):329-339 e323","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"3417_CR73","doi-asserted-by":"crossref","unstructured":"Font P, Loscertales J, Soto C, et al. (2015) Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol 94(4):565\u2013573","DOI":"10.1007\/s00277-014-2252-4"},{"issue":"4","key":"3417_CR74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.leu.2404564","volume":"21","author":"E Verburgh","year":"2007","unstructured":"Verburgh E, Achten R, Louw VJ et al (2007) A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 21(4):668\u2013677","journal-title":"Leukemia"},{"key":"3417_CR75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2017.02.008","volume":"57","author":"C Strupp","year":"2017","unstructured":"Strupp C, Nachtkamp K, Hildebrandt B et al (2017) New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res 57:78\u201384","journal-title":"Leuk Res"},{"issue":"33","key":"3417_CR76","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","volume":"39","author":"A Nazha","year":"2021","unstructured":"Nazha A, Komrokji R, Meggendorfer M et al (2021) Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol 39(33):3737\u20133746","journal-title":"J Clin Oncol"},{"issue":"12","key":"3417_CR77","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465","journal-title":"Blood"},{"issue":"1","key":"3417_CR78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ajcp\/aqx043","volume":"148","author":"E Margolskee","year":"2017","unstructured":"Margolskee E, Hasserjian RP, Hassane D et al (2017) Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis. Am J Clin Pathol 148(1):49\u201357","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"3417_CR79","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon AJ, Madanat Y et al (2022) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv 6(9):2847\u20132853","journal-title":"Blood Adv"},{"issue":"1","key":"3417_CR80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1309\/AJCPRKYAT6EZQHC7","volume":"144","author":"SA Wang","year":"2015","unstructured":"Wang SA, Hasserjian RP (2015) Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities. Am J Clin Pathol 144(1):44\u201360","journal-title":"Am J Clin Pathol"},{"key":"3417_CR81","doi-asserted-by":"crossref","unstructured":"Yabe M, Omarbekova AZ, Hsu M, et al. (2021) TP53 combined phenotype score is associated with the clinical outcome of TP53-mutated myelodysplastic syndromes. Cancers (Basel) 13(21)","DOI":"10.3390\/cancers13215502"},{"issue":"4","key":"3417_CR82","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/modpathol.2014.153","volume":"28","author":"AH Cleven","year":"2015","unstructured":"Cleven AH, Nardi V, Ok CY et al (2015) High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol 28(4):552\u2013563","journal-title":"Mod Pathol"},{"issue":"4","key":"3417_CR83","first-page":"417","volume":"11","author":"EN Oliva","year":"2021","unstructured":"Oliva EN, Latagliata R, Sabattini E et al (2021) Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. Am J Blood Res 11(4):417\u2013426","journal-title":"Am J Blood Res"},{"issue":"10","key":"3417_CR84","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP et al (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 26(10):1549\u20131556","journal-title":"Nat Med"},{"issue":"3","key":"3417_CR85","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C et al (2016) Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 30(3):666\u2013673","journal-title":"Leukemia"},{"issue":"3","key":"3417_CR86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-021-00446-y","volume":"11","author":"R Kanagal-Shamanna","year":"2021","unstructured":"Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P et al (2021) Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52","journal-title":"Blood Cancer J"},{"issue":"7","key":"3417_CR87","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","volume":"33","author":"D Haase","year":"2019","unstructured":"Haase D, Stevenson KE, Neuberg D et al (2019) TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia 33(7):1747\u20131758","journal-title":"Leukemia"},{"issue":"19","key":"3417_CR88","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1200\/JCO.2011.38.7340","volume":"30","author":"V Nardi","year":"2012","unstructured":"Nardi V, Winkfield KM, Ok CY et al (2012) Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 30(19):2340\u20132347","journal-title":"J Clin Oncol"},{"issue":"3","key":"3417_CR89","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","volume":"35","author":"A Kuendgen","year":"2021","unstructured":"Kuendgen A, Nomdedeu M, Tuechler H et al (2021) Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia 35(3):835\u2013849","journal-title":"Leukemia"},{"issue":"1","key":"3417_CR90","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2013.191","volume":"28","author":"CY Ok","year":"2014","unstructured":"Ok CY, Hasserjian RP, Fox PS et al (2014) Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28(1):185\u2013189","journal-title":"Leukemia"},{"issue":"1","key":"3417_CR91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H et al (2017) Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100\u2013111","journal-title":"Lancet Oncol"},{"issue":"7","key":"3417_CR92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-022-00703-8","volume":"12","author":"MV Shah","year":"2022","unstructured":"Shah MV, Mangaonkar AA, Begna KH et al (2022) Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J 12(7):106","journal-title":"Blood Cancer J"},{"issue":"4","key":"3417_CR93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1093526618822108","volume":"22","author":"KM Chisholm","year":"2019","unstructured":"Chisholm KM, Denton C, Keel S et al (2019) Bone marrow morphology associated with germline RUNX1 mutations in patients with familial platelet disorder with associated myeloid malignancy. Pediatr Dev Pathol 22(4):315\u2013328","journal-title":"Pediatr Dev Pathol"},{"issue":"10","key":"3417_CR94","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","volume":"102","author":"R Kanagal-Shamanna","year":"2017","unstructured":"Kanagal-Shamanna R, Loghavi S, DiNardo CD et al (2017) Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661\u20131670","journal-title":"Haematologica"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03417-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:19:48Z","timestamp":1674847188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03417-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3417"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03417-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"26 October 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}